1846449-200.png

Target Discovery

  • Identifying novel disease targets 
  • Identifying targets that are essential for disease progression in a given indication or patient population (think in-silico CRISPR screening)
  • Uncovering genetic interactions (such as synthetic lethality or sickness) that could be exploited therapeutically 
  • Identifying targets that contribute to organ or patient specific toxicities 

 

Lead Identification

  • Identifying new compounds or combinations that could modulate a given disease phenotype or treat resistant patients 
  • Pinpointing small molecules that bind (or not bind) a specific set of targets
  • Identifying synergistic combinations for a given genotype or patient subpopulation
603698-200.png

1061260-200.png

Mechanism of Action Discovery

  • Uncovering on and off target bindings for a given small molecule
  • Identifying activated or modulated pathways following treatment with a given drug
  • Providing insights into the pathways or targets involved in patient or organ specific adverse event

 

ADME/Toxicity

  • Predicting the likelihood of organ specific adverse events (such as drug induced liver injury or pleural effusion) for a given compound
  • Identifying contributing factors into an observed toxic effects (for instance, differentiating between structure vs target derived toxicities)
  • Predicting blood/brain barrier permeability
724856-200.png

1070134-200.png

Therapeutic Positioning and Biomarkers 

  • Identify top therapeutic opportunities for assets in development or shelved assets
  • Uncover biomarkers of response that could be used to select optimal patient subgroups
  • Identify other drugs that could be paired with a given compound for synergistic combination therapies